HomeCompareANPCY vs BTI

ANPCY vs BTI: Dividend Comparison 2026

ANPCY yields 2985.07% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANPCY wins by $433539968075.08M in total portfolio value
10 years
ANPCY
ANPCY
● Live price
2985.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$433539968075.12M
Annual income
$406,736,225,519,142,500.00
Full ANPCY calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ANPCY vs BTI

📍 ANPCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANPCYBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANPCY + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANPCY pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANPCY
Annual income on $10K today (after 15% tax)
$253,731.34/yr
After 10yr DRIP, annual income (after tax)
$345,725,791,691,271,200.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ANPCY beats the other by $345,725,791,691,268,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANPCY + BTI for your $10,000?

ANPCY: 50%BTI: 50%
100% BTI50/50100% ANPCY
Portfolio after 10yr
$216769984037.58M
Annual income
$203,368,112,759,572,670.00/yr
Blended yield
93.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ANPCY
No analyst data
Altman Z
-11.9
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANPCY buys
0
BTI buys
0
No recent congressional trades found for ANPCY or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANPCYBTI
Forward yield2985.07%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$433539968075.12M$37.7K
Annual income after 10y$406,736,225,519,142,500.00$2,786.64
Total dividends collected$431686299125.80M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ANPCY vs BTI ($10,000, DRIP)

YearANPCY PortfolioANPCY Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$309,207$298,507.46$11,299$598.92+$297.9KANPCY
2$8,957,089$8,626,236.93$12,794$703.91+$8.94MANPCY
3$243,120,454$233,536,368.64$14,518$829.07+$243.11MANPCY
4$6,184,279,490$5,924,140,604.30$16,513$978.64+$6184.26MANPCY
5$147,451,722,719$140,834,543,664.57$18,827$1,157.84+$147451.70MANPCY
6$3,296,013,356,428$3,138,240,013,119.13$21,518$1,373.12+$3296013.33MANPCY
7$69,087,118,460,072$65,560,384,168,694.19$24,657$1,632.46+$69087118.44MANPCY
8$1,358,221,282,082,432$1,284,298,065,330,154.50$28,329$1,945.74+$1358221282.05MANPCY
9$25,050,226,687,827,436$23,596,929,915,999,230.00$32,637$2,325.33+$25050226687.79MANPCY
10$433,539,968,075,117,900$406,736,225,519,142,500.00$37,708$2,786.64+$433539968075.08MANPCY

ANPCY vs BTI: Complete Analysis 2026

ANPCYStock

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Full ANPCY Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ANPCY vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANPCY vs SCHDANPCY vs JEPIANPCY vs OANPCY vs KOANPCY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.